Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Read Ipsos latest PoV, where we explore these topics in more depth: Ipsos has tracked MASH treatment since 2017
Volume is now expected to decline within the range of 1.4% to 3.4% in 2026, an increase from Big Chalks end-of-year prediction of 1.1% to 3.1%
Both trials suggest maintenance strategies, such as lower-dose injections or oral therapies, could offer patients more flexible, potentially more convenient options for sustaining weight loss after intensive treatment
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
US$ 28.44
US$ 23.76
US$ 21.01
US$ 24.06
US$ 25.60
US$ 23.88
US$ 21.70
